Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm (1)
Mandate

Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm

September 23, 2019 Capital Markets and Public M&A

Vinge advises Vicore Pharma Holding AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market.

The prospectus was published on 16 September 2019 and the trading on Nasdaq Stockholm will commence on 27 September 2019.

Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs in preclinical or clinical phase.

Vinge’s team has primarily consisted of Jesper Schönbeck, Nils Fredrik Dehlin, Astrid Isberg, Emelie Svanberg, Viktor Bergsten and Sofia Bergenstråhle.

Related

Vinge advises Smart Eye Aktiebolag (publ) on its first SEK 300 million bond issue

 Vinge has advised Smart Eye Aktiebolag (publ) (“Smart Eye”) on the company’s first issue of senior unsecured bonds in an aggregate principal amount of SEK 300 million, under a framework of up to SEK 600 million. Skandinaviska Enskilda Banken AB (publ) acted as sole bookrunner in connection with the bond issue.
December 12, 2025

Vinge advises Nordstjernan in connection with the investment in Circura Group

Vinge has advised Nordstjernan in connection with its investment in newly established Circura Group.
December 12, 2025

Vinge has advised Axcel VI and Currentum in connection with the acquisition of Klarins Rör

 Vinge has advised Axcel VI and the Currentum Group in connection with the acquisition of Klarins Rör i Göteborg AB (“Klarins Rör”).
December 09, 2025